Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Sep 1;180(3):1037–1046. doi: 10.1084/jem.180.3.1037

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

PMCID: PMC2191626  PMID: 7520465

Abstract

The hepatitis B virus (HBV) nucleocapsid antigen (HBcAg) was investigated as a carrier moiety for the immunodominant circumsporozoite (CS) protein repeat epitopes of Plasmodium falciparum and the rodent malaria agent P. berghei. For this purpose hybrid genes coding for [NANP]4 (C75CS2) or [DP4NPN]2 (C75CS1) as internal inserts in HBcAg (between amino acids 75 and 81) were constructed and expressed in recombinant Salmonella typhimurium. The resulting hybrid HBcAg-CS polypeptides purified from S. typhimurium were particulate and displayed CS and HBc antigenicity, however, the HBc antigenicity was reduced compared to native recombinant HBcAg. Immunization of several mouse strains with HBcAg-CS1 and HBcAg-CS2 particles resulted in high titer, P.berghei- or P.falciparum-specific anti-CS antibodies representing all murine immunoglobulin G isotypes. The possible influence of carrier-specific immunosuppression was examined, and preexisting immunity to HBcAg did not significantly affect the immunogenicity of the CS epitopes within HBcAg-CS1 particles. Similarly, the choice of adjuvant did not significantly alter the immunogenicity of HBcAg-CS hybrid particles. Immunization in complete or incomplete Freund's adjuvant or alum resulted in equivalent anti-HBc and anti-CS humoral responses. Examination of T cell recognition of HBcAg-CS particles revealed that HBcAg-specific T cells were universally primed and CS-specific T cells were primed if the insert contained a CS-specific T cell recognition site. This indicates that the internal site in HBcAg is permissive for the inclusion of heterologous pathogen-specific T as well as B cell epitopes. Most importantly, 90 and 100% of BALB/c mice immunized with HBcAg-CS1 particles were protected against a P. berghei challenge infection in two independent experiments. Therefore, hybrid HBcAg-CS particles may represent a useful approach for future malaria vaccine development.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ak M., Bower J. H., Hoffman S. L., Sedegah M., Lees A., Carter M., Beaudoin R. L., Charoenvit Y. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites. Infect Immun. 1993 Jun;61(6):2493–2497. doi: 10.1128/iai.61.6.2493-2497.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ballou W. R., Hoffman S. L., Sherwood J. A., Hollingdale M. R., Neva F. A., Hockmeyer W. T., Gordon D. M., Schneider I., Wirtz R. A., Young J. F. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281. doi: 10.1016/s0140-6736(87)90540-x. [DOI] [PubMed] [Google Scholar]
  3. Borisova G. P., Berzins I., Pushko P. M., Pumpen P., Gren E. J., Tsibinogin V. V., Loseva V., Ose V., Ulrich R., Siakkou H. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett. 1989 Dec 18;259(1):121–124. doi: 10.1016/0014-5793(89)81509-1. [DOI] [PubMed] [Google Scholar]
  4. Borisova G., Arya B., Dislers A., Borschukova O., Tsibinogin V., Skrastina D., Eldarov M. A., Pumpens P., Skryabin K. G., Grens E. Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J Virol. 1993 Jun;67(6):3696–3701. doi: 10.1128/jvi.67.6.3696-3701.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Charoenvit Y., Collins W. E., Jones T. R., Millet P., Yuan L., Campbell G. H., Beaudoin R. L., Broderson J. R., Hoffman S. L. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science. 1991 Feb 8;251(4994):668–671. doi: 10.1126/science.1704150. [DOI] [PubMed] [Google Scholar]
  6. Charoenvit Y., Mellouk S., Cole C., Bechara R., Leef M. F., Sedegah M., Yuan L. F., Robey F. A., Beaudoin R. L., Hoffman S. L. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol. 1991 Feb 1;146(3):1020–1025. [PubMed] [Google Scholar]
  7. Clarke B. E., Newton S. E., Carroll A. R., Francis M. J., Appleyard G., Syred A. D., Highfield P. E., Rowlands D. J., Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. 1987 Nov 26-Dec 2Nature. 330(6146):381–384. doi: 10.1038/330381a0. [DOI] [PubMed] [Google Scholar]
  8. Curtiss R., 3rd, Kelly S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987 Dec;55(12):3035–3043. doi: 10.1128/iai.55.12.3035-3043.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Del Giudice G., Cooper J. A., Merino J., Verdini A. S., Pessi A., Togna A. R., Engers H. D., Corradin G., Lambert P. H. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. J Immunol. 1986 Nov 1;137(9):2952–2955. [PubMed] [Google Scholar]
  10. Egan J. E., Weber J. L., Ballou W. R., Hollingdale M. R., Majarian W. R., Gordon D. M., Maloy W. L., Hoffman S. L., Wirtz R. A., Schneider I. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science. 1987 Apr 24;236(4800):453–456. doi: 10.1126/science.3551073. [DOI] [PubMed] [Google Scholar]
  11. Good M. F., Berzofsky J. A., Maloy W. L., Hayashi Y., Fujii N., Hockmeyer W. T., Miller L. H. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med. 1986 Aug 1;164(2):655–660. doi: 10.1084/jem.164.2.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Good M. F., Maloy W. L., Lunde M. N., Margalit H., Cornette J. L., Smith G. L., Moss B., Miller L. H., Berzofsky J. A. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science. 1987 Feb 27;235(4792):1059–1062. doi: 10.1126/science.2434994. [DOI] [PubMed] [Google Scholar]
  13. Herrington D. A., Clyde D. F., Losonsky G., Cortesia M., Murphy J. R., Davis J., Baqar S., Felix A. M., Heimer E. P., Gillessen D. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987 Jul 16;328(6127):257–259. doi: 10.1038/328257a0. [DOI] [PubMed] [Google Scholar]
  14. Herzenberg L. A., Tokuhisa T. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med. 1982 Jun 1;155(6):1730–1740. doi: 10.1084/jem.155.6.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Houghten R. A. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A. 1985 Aug;82(15):5131–5135. doi: 10.1073/pnas.82.15.5131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Imai M., Nomura M., Gotanda T., Sano T., Tachibana K., Miyamoto H., Takahashi K., Toyama S., Miyakawa Y., Mayumi M. Demonstration of two distinct antigenic determinants on hepatitis B e antigen by monoclonal antibodies. J Immunol. 1982 Jan;128(1):69–72. [PubMed] [Google Scholar]
  17. Milich D. R., McLachlan A., Moriarty A., Thornton G. B. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol. 1987 Aug 15;139(4):1223–1231. [PubMed] [Google Scholar]
  18. Milich D. R., McLachlan A., Stahl S., Wingfield P., Thornton G. B., Hughes J. L., Jones J. E. Comparative immunogenicity of hepatitis B virus core and E antigens. J Immunol. 1988 Nov 15;141(10):3617–3624. [PubMed] [Google Scholar]
  19. Milich D. R., McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986 Dec 12;234(4782):1398–1401. doi: 10.1126/science.3491425. [DOI] [PubMed] [Google Scholar]
  20. Milich D. R., McLachlan A., Thornton G. B., Hughes J. L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature. 1987 Oct 8;329(6139):547–549. doi: 10.1038/329547a0. [DOI] [PubMed] [Google Scholar]
  21. Milich D. R. T- and B-cell recognition of hepatitis B viral antigens. Immunol Today. 1988 Dec;9(12):380–386. doi: 10.1016/0167-5699(88)91239-X. [DOI] [PubMed] [Google Scholar]
  22. Nardin E. H., Nussenzweig V., Nussenzweig R. S., Collins W. E., Harinasuta K. T., Tapchaisri P., Chomcharn Y. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med. 1982 Jul 1;156(1):20–30. doi: 10.1084/jem.156.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nussenzweig R., Vanderberg J., Most H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med. 1969 Sep;134(10):1176–1182. [PubMed] [Google Scholar]
  24. Okamoto H., Imai M., Usuda S., Tanaka E., Tachibana K., Mishiro S., Machida A., Nakamura T., Miyakawa Y., Mayumi M. Hemagglutination assay of polypeptide coded by the pre-S region of hepatitis B virus DNA with monoclonal antibody: correlation of pre-S polypeptide with the receptor for polymerized human serum albumin in serums containing hepatitis B antigens. J Immunol. 1985 Feb;134(2):1212–1216. [PubMed] [Google Scholar]
  25. Romero P. J., Tam J. P., Schlesinger D., Clavijo P., Gibson H., Barr P. J., Nussenzweig R. S., Nussenzweig V., Zavala F. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei. Eur J Immunol. 1988 Dec;18(12):1951–1957. doi: 10.1002/eji.1830181213. [DOI] [PubMed] [Google Scholar]
  26. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 1987 Dec 17;330(6149):664–666. doi: 10.1038/330664a0. [DOI] [PubMed] [Google Scholar]
  27. Schödel F., Milich D. R., Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol. 1990 Dec 15;145(12):4317–4321. [PubMed] [Google Scholar]
  28. Schödel F., Moriarty A. M., Peterson D. L., Zheng J. A., Hughes J. L., Will H., Leturcq D. J., McGee J. S., Milich D. R. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol. 1992 Jan;66(1):106–114. doi: 10.1128/jvi.66.1.106-114.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schödel F., Peterson D., Hughes J., Milich D. Hepatitis B virus core particles as a vaccine carrier moiety. Int Rev Immunol. 1994;11(2):153–165. doi: 10.3109/08830189409061723. [DOI] [PubMed] [Google Scholar]
  30. Seifer M., Standring D. N. Stability governs the apparent expression of "particulate" hepatitis B e antigen by mutant hepatitis B virus core particles. Virology. 1993 Sep;196(1):70–78. doi: 10.1006/viro.1993.1455. [DOI] [PubMed] [Google Scholar]
  31. Spitalny G. L., Nussenzweig R. S. Plasmodium berghei: relationship between protective immunity and anti-sporozoite (CSP) antibody in mice. Exp Parasitol. 1973 Feb;33(1):168–178. doi: 10.1016/0014-4894(73)90022-2. [DOI] [PubMed] [Google Scholar]
  32. Spitalny G. L., Rivera-Ortiz C. I., Nussenzweig R. S. Plasmodium berghei: the spleen in sporozoite-induced immunity to mouse malaria. Exp Parasitol. 1976 Oct;40(2):179–188. doi: 10.1016/0014-4894(76)90080-1. [DOI] [PubMed] [Google Scholar]
  33. Stahl S. J., Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6283–6287. doi: 10.1073/pnas.86.16.6283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Takahashi K., Machida A., Funatsu G., Nomura M., Usuda S., Aoyagi S., Tachibana K., Miyamoto H., Imai M., Nakamura T. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol. 1983 Jun;130(6):2903–2907. [PubMed] [Google Scholar]
  35. Tam J. P., Clavijo P., Lu Y. A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med. 1990 Jan 1;171(1):299–306. doi: 10.1084/jem.171.1.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Weiss W. R., Sedegah M., Beaudoin R. L., Miller L. H., Good M. F. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A. 1988 Jan;85(2):573–576. doi: 10.1073/pnas.85.2.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zavala F., Tam J. P., Barr P. J., Romero P. J., Ley V., Nussenzweig R. S., Nussenzweig V. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med. 1987 Nov 1;166(5):1591–1596. doi: 10.1084/jem.166.5.1591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Zavala F., Tam J. P., Hollingdale M. R., Cochrane A. H., Quakyi I., Nussenzweig R. S., Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985 Jun 21;228(4706):1436–1440. doi: 10.1126/science.2409595. [DOI] [PubMed] [Google Scholar]
  39. von Brunn A., Brand M., Reichhuber C., Morys-Wortmann C., Deinhardt F., Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine. 1993;11(8):817–824. doi: 10.1016/0264-410x(93)90356-3. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES